MIRA Pharmaceuticals (NASDAQ:MIRA) Releases Earnings Results, Beats Estimates By $0.06 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) issued its quarterly earnings results on Tuesday. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.06, FiscalAI reports.

MIRA Pharmaceuticals Stock Performance

Shares of MIRA stock traded up $0.11 during mid-day trading on Tuesday, hitting $1.07. 90,832 shares of the stock traded hands, compared to its average volume of 153,211. MIRA Pharmaceuticals has a twelve month low of $0.73 and a twelve month high of $2.45. The company’s 50-day simple moving average is $1.20 and its 200-day simple moving average is $1.36. The firm has a market cap of $44.81 million, a price-to-earnings ratio of -0.70 and a beta of 1.78.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MIRA. Rodman & Renshaw started coverage on shares of MIRA Pharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MIRA. Creative Planning purchased a new stake in MIRA Pharmaceuticals during the second quarter valued at about $27,000. XTX Topco Ltd acquired a new stake in shares of MIRA Pharmaceuticals during the second quarter valued at approximately $26,000. Two Sigma Investments LP raised its holdings in shares of MIRA Pharmaceuticals by 129.8% during the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of MIRA Pharmaceuticals by 100.0% in the 4th quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after acquiring an additional 136,438 shares in the last quarter. Institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.